

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday 4 December 2018

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler (Chair)	Present for all notes
	2. Dr Sanjeev Patel	Present for all notes
	3. Dr Mark Glover	Present for all notes
	4. Dr Carlo Berti	Present for all notes
	5. Mr Christopher O'Regan	Present for all notes
	6. Mr Gareth Hooper	Present for all notes
	7. Professor John Cairns	Present for all notes
	8. Mr Mark Chapman	Present for all notes
	9. Dr Megan John	Present for all notes
	10. Dr Nicholas Latimer	Present for all notes
	11. Professor Stephen Palmer	Present for all notes
	12. Dr Stephen Smith	Present for all notes
	13. Mr William Turner	Present for all notes
	14. Professor Nicky Welton	Present for all notes
	15. Mr Nigel Westwood	Present for all notes

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sandra Aleknave	Administrator, National Institute for Health and Care Excellence	Present for all notes
Adam Brooke	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Ahmed Elsada	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes

Professor Noel Clarke	Professor of Urological Oncology, The Christie and Salford Royal Hospitals, Manchester - clinical expert nominated by the British Association of Urological Surgeons	Present for notes 6 to 15
Dr Alison Tree	Consultant Clinical Oncologist, Royal Marsden Hospital - clinical expert nominated by the Royal College of Physicians	Present for notes 6 to 15
Mr Anthony Good	Patient expert, nominated by Prostate Cancer UK	Present for notes 6 to 15
Mr Ronald Keats	Patient expert, nominated by Prostate Cancer UK	Present for notes 6 to 15
Professor Peter Clark	Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF	Present for all notes
Professor Craig Ramsay	Director of Health Services Research Unit, Aberdeen HTA Group	Present for notes 6 to 17
Dr Graham Scotland	Senior Research Fellow, Aberdeen HTA Group	Present for notes 6 to 17

Non-public attendees:

Helen Barnett	Medical Editor, NICE	Present for all notes
Jeanette Kusel	Director, NICE Scientific Advice	Present for all notes
Edgar Masanga	Business Analyst, NICE	Present for all notes
Alan Moore	Technical Analyst, NICE	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
2. The Chair welcomed Gareth Hooper and Megan John to their first meeting as members of the Appraisal Committee.
3. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Jeanette Kusel, Edgar Masanga and Alan Moore.

4. Apologies were received from Mr Diar Fattah, Ms Susan Faulds, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Professor Allyson Pollock, Professor Sarah Wild and Dr Stuart Williams.

Any other Business

5. The Committee were given an update on the progress of appraisals discussed at previous meetings.

Notes from the last meeting

6. The minutes of the Committee meetings held on 6 September 2018, 3 October 2018 and 6 November 2018 were approved.

Appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359]

Part 1 – Open session

7. The Chair welcomed the invited experts: Professor Noel Clarke, Dr Alison Tree, Mr Anthony Good, Mr Ronald Keats, Professor Peter Clark, Professor Craig Ramsay and Dr Graham Scotland to the meeting and they introduced themselves to the Committee.
8. The Chair welcomed company representatives from Astellas to the meeting.
9. The Chair asked all Committee members to declare any relevant interests
 - 9.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Mark Glover, Dr Carlo Berti, Mr Christopher O'Regan, Mr Gareth Hooper, Professor John Cairns, Mr Mark Chapman, Dr Megan John, Dr Nicholas Latimer, Professor Stephen Palmer, Dr Stephen Smith, Mr William Turner, Professor Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
10. The Chair asked all NICE Staff to declare any relevant interests.
 - 10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 11.1. Mr Anthony Good, Mr Ronald Keats, Professor Peter Clark, Professor Craig Ramsay and Dr Graham Scotland declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-

specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].

- 11.2. Professor Noel Clarke declared a personal non-specific financial interest as he has received honoraria for teaching and trial planning from AstraZeneca, Astellas, Bayer, Ferring, Janssen, Pfizer and Sanofi-Aventis. He also declared that he has received research funding from AstraZeneca and Janssen.
 - 11.2.1. It was agreed that this declaration would not prevent Professor Clarke from participating in this section of the meeting.
- 11.3. Dr Alison Tree declared a personal non-specific financial interest as she has received either honoraria or educational travel grants from the following companies: Accuray, Elekta, Ferring, Astellas, Janssen, Genesis healthcare and Bayer. She also declared that she has received grant funding from Accuray, Elekta and MSD.
 - 11.3.1. It was agreed that this declaration would not prevent Dr Tree from participating in this section of the meeting
12. The Chair introduced the lead team, Mr William Turner, Mr Chris O'Regan and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.
17. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
18. The Committee continued to discuss the clinical and cost effectiveness of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
 - 18.1. The committee decision was based on consensus.
19. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

20. Tuesday 22 January 2019 from 10am at Prospero House, 241 Borough High Street, London, SE1 1GA.